BioSpecifics Technologies Corp. (BSTC) and Cellular Biomedicine Group Inc. (NASDAQ:CBMG) Comparison side by side

BioSpecifics Technologies Corp. (NASDAQ:BSTC) and Cellular Biomedicine Group Inc. (NASDAQ:CBMG), both competing one another are Biotechnology companies. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioSpecifics Technologies Corp. 32.96M 15.01 20.05M 2.40 29.63
Cellular Biomedicine Group Inc. N/A 1458.61 38.95M -2.20 0.00

Table 1 demonstrates BioSpecifics Technologies Corp. and Cellular Biomedicine Group Inc.’s gross revenue, earnings per share and valuation.


Table 2 has BioSpecifics Technologies Corp. and Cellular Biomedicine Group Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies Corp. 60.83% 21.8% 20.7%
Cellular Biomedicine Group Inc. 0.00% -46.2% -43.2%

Volatility and Risk

A beta of 1.29 shows that BioSpecifics Technologies Corp. is 29.00% more volatile than Standard and Poor’s 500. Cellular Biomedicine Group Inc.’s 3.18 beta is the reason why it is 218.00% more volatile than Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of BioSpecifics Technologies Corp. are 48.4 and 48.4. Competitively, Cellular Biomedicine Group Inc. has 8.9 and 8.9 for Current and Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than Cellular Biomedicine Group Inc.

Analyst Ratings

BioSpecifics Technologies Corp. and Cellular Biomedicine Group Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioSpecifics Technologies Corp. 0 0 1 3.00
Cellular Biomedicine Group Inc. 0 0 1 3.00

The average target price of BioSpecifics Technologies Corp. is $85, with potential upside of 25.18%. Meanwhile, Cellular Biomedicine Group Inc.’s average target price is $26, while its potential upside is 51.87%. Based on the analysts opinion we can conclude, Cellular Biomedicine Group Inc. is looking more favorable than BioSpecifics Technologies Corp.

Insider and Institutional Ownership

BioSpecifics Technologies Corp. and Cellular Biomedicine Group Inc. has shares held by institutional investors as follows: 61.3% and 19.3%. Insiders held roughly 2.5% of BioSpecifics Technologies Corp.’s shares. Competitively, insiders own roughly 39.63% of Cellular Biomedicine Group Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%
Cellular Biomedicine Group Inc. 4.14% 6.13% -7.28% -5.94% 11.6% 6.8%

For the past year BioSpecifics Technologies Corp. was more bullish than Cellular Biomedicine Group Inc.


On 9 of the 11 factors BioSpecifics Technologies Corp. beats Cellular Biomedicine Group Inc.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.